Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8197)	1/5/1999 8:40:00 PM
From: aknahow	Respond to of 17367

Cacaito, perhaps I missed it but I did not think the meningococcemia p III trial was double tailed, with a high and lower Glasgow score being used. I think some concern is that the mortality rate of the placebo group is much lower than 20%. Not a concern if in fact great if fewer kids get hurt, a concern only in determination of the effectiveness of Neuprex. If the placebo mortality rate is 10% and the Neuprex rate is 6% I would like to know how large of sample is needed to make this statistically significant. I share your thoughts on the information provided in many non scientific publications. Meningitis and meningococcal sepsis are at times considered the same thing. A friend made me think that extending the trial for a few more weeks would not be bad. If indeed Neuprex was not close to being effective the thought is that a DSMB would not recomend extension. Extension would make sense if the DSMB felt that adding 100 more patients would improve the p level, if the difference between Neuprex and the placebo continued at its present rate. At any rate we are in January and the trial has not been halted. The U.K. site that at least discloses total case loads for meningococcal sepsis has not ben updated since 20 November, so I have been unable to even report this data, which has little real value in any event.